vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Rockwell Automation (ROK). Click either name above to swap in a different company.
Rockwell Automation is the larger business by last-quarter revenue ($2.1B vs $1.1B, roughly 1.8× Elanco Animal Health Inc). Rockwell Automation runs the higher net margin — 14.5% vs -24.1%, a 38.6% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 11.9%). Rockwell Automation produced more free cash flow last quarter ($170.0M vs $46.0M). Over the past eight quarters, Rockwell Automation's revenue compounded faster (-0.5% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Rockwell Automation, Inc. is an American provider of industrial automation and digital transformation technologies headquartered in Milwaukee, Wisconsin. Its brands include Allen-Bradley, FactoryTalk software and LifecycleIQ Services. Rockwell Automation employs approximately 27,000 people and has customers in more than 100 countries worldwide.
ELAN vs ROK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $2.1B |
| Net Profit | $-276.0M | $305.0M |
| Gross Margin | 51.5% | 48.3% |
| Operating Margin | -22.6% | 20.7% |
| Net Margin | -24.1% | 14.5% |
| Revenue YoY | 12.2% | 11.9% |
| Net Profit YoY | -3350.0% | 65.8% |
| EPS (diluted) | $-0.55 | $2.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.1B | $2.3B | ||
| Q2 25 | $1.2B | $2.1B | ||
| Q1 25 | $1.2B | $2.0B | ||
| Q4 24 | $1.0B | $1.9B | ||
| Q3 24 | $1.0B | $2.0B | ||
| Q2 24 | $1.2B | $2.1B | ||
| Q1 24 | $1.2B | $2.1B |
| Q4 25 | $-276.0M | $305.0M | ||
| Q3 25 | $-34.0M | $138.0M | ||
| Q2 25 | $11.0M | $295.0M | ||
| Q1 25 | $67.0M | $252.0M | ||
| Q4 24 | $-8.0M | $184.0M | ||
| Q3 24 | $364.0M | $239.1M | ||
| Q2 24 | $-50.0M | $232.0M | ||
| Q1 24 | $32.0M | $266.2M |
| Q4 25 | 51.5% | 48.3% | ||
| Q3 25 | 53.4% | 69.4% | ||
| Q2 25 | 57.5% | 40.9% | ||
| Q1 25 | 57.3% | 40.5% | ||
| Q4 24 | 50.9% | 38.4% | ||
| Q3 24 | 52.2% | 37.9% | ||
| Q2 24 | 58.2% | 38.8% | ||
| Q1 24 | 57.3% | 39.2% |
| Q4 25 | -22.6% | 20.7% | ||
| Q3 25 | -4.4% | 2.7% | ||
| Q2 25 | 2.0% | 16.0% | ||
| Q1 25 | 5.0% | 14.9% | ||
| Q4 24 | -5.0% | 17.1% | ||
| Q3 24 | 54.3% | 13.5% | ||
| Q2 24 | -2.7% | 12.4% | ||
| Q1 24 | 1.0% | 14.6% |
| Q4 25 | -24.1% | 14.5% | ||
| Q3 25 | -3.0% | 6.0% | ||
| Q2 25 | 0.9% | 13.8% | ||
| Q1 25 | 5.6% | 12.6% | ||
| Q4 24 | -0.8% | 9.8% | ||
| Q3 24 | 35.3% | 11.7% | ||
| Q2 24 | -4.2% | 11.3% | ||
| Q1 24 | 2.7% | 12.5% |
| Q4 25 | $-0.55 | $2.69 | ||
| Q3 25 | $-0.07 | $1.24 | ||
| Q2 25 | $0.02 | $2.60 | ||
| Q1 25 | $0.13 | $2.22 | ||
| Q4 24 | $-0.01 | $1.61 | ||
| Q3 24 | $0.73 | $2.09 | ||
| Q2 24 | $-0.10 | $2.02 | ||
| Q1 24 | $0.06 | $2.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $444.0M |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $3.7B |
| Total Assets | $13.4B | $11.2B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $444.0M | ||
| Q3 25 | $505.0M | $468.0M | ||
| Q2 25 | $539.0M | $495.0M | ||
| Q1 25 | $487.0M | $456.0M | ||
| Q4 24 | $468.0M | $477.0M | ||
| Q3 24 | $490.0M | $471.3M | ||
| Q2 24 | $416.0M | $407.0M | ||
| Q1 24 | $345.0M | $470.5M |
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | $2.6B | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | $2.6B | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.8B | — |
| Q4 25 | $6.5B | $3.7B | ||
| Q3 25 | $6.7B | $3.7B | ||
| Q2 25 | $6.8B | $3.5B | ||
| Q1 25 | $6.4B | $3.4B | ||
| Q4 24 | $6.1B | $3.4B | ||
| Q3 24 | $6.5B | $3.5B | ||
| Q2 24 | $5.9B | $3.3B | ||
| Q1 24 | $6.1B | $3.5B |
| Q4 25 | $13.4B | $11.2B | ||
| Q3 25 | $13.6B | $11.2B | ||
| Q2 25 | $13.7B | $11.2B | ||
| Q1 25 | $12.9B | $11.0B | ||
| Q4 24 | $12.6B | $10.9B | ||
| Q3 24 | $13.3B | $11.2B | ||
| Q2 24 | $13.8B | $11.2B | ||
| Q1 24 | $14.0B | $11.4B |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | 0.72× | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | 0.73× | ||
| Q2 24 | 0.96× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $234.0M |
| Free Cash FlowOCF − Capex | $46.0M | $170.0M |
| FCF MarginFCF / Revenue | 4.0% | 8.1% |
| Capex IntensityCapex / Revenue | 5.4% | 3.0% |
| Cash ConversionOCF / Net Profit | — | 0.77× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $234.0M | ||
| Q3 25 | $219.0M | $454.0M | ||
| Q2 25 | $237.0M | $527.0M | ||
| Q1 25 | $-4.0M | $199.0M | ||
| Q4 24 | $177.0M | $364.0M | ||
| Q3 24 | $162.0M | $432.3M | ||
| Q2 24 | $200.0M | $279.1M | ||
| Q1 24 | $2.0M | $119.8M |
| Q4 25 | $46.0M | $170.0M | ||
| Q3 25 | $127.0M | — | ||
| Q2 25 | $180.0M | $489.0M | ||
| Q1 25 | $-69.0M | $171.0M | ||
| Q4 24 | $130.0M | $293.0M | ||
| Q3 24 | $120.0M | — | ||
| Q2 24 | $166.0M | $238.4M | ||
| Q1 24 | $-22.0M | $68.6M |
| Q4 25 | 4.0% | 8.1% | ||
| Q3 25 | 11.2% | — | ||
| Q2 25 | 14.5% | 22.8% | ||
| Q1 25 | -5.8% | 8.5% | ||
| Q4 24 | 12.7% | 15.6% | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 14.0% | 11.6% | ||
| Q1 24 | -1.8% | 3.2% |
| Q4 25 | 5.4% | 3.0% | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 4.6% | 1.8% | ||
| Q1 25 | 5.4% | 1.4% | ||
| Q4 24 | 4.6% | 3.8% | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | 2.9% | 2.0% | ||
| Q1 24 | 2.0% | 2.4% |
| Q4 25 | — | 0.77× | ||
| Q3 25 | — | 3.29× | ||
| Q2 25 | 21.55× | 1.79× | ||
| Q1 25 | -0.06× | 0.79× | ||
| Q4 24 | — | 1.98× | ||
| Q3 24 | 0.45× | 1.81× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | 0.06× | 0.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
ROK
| Productsand Solutions | $1.9B | 89% |
| Lifecycle Services Segment | $259.0M | 12% |
